LONDON/NEW YORK/TOKYO (Reuters) – Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan’s Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company this year.